Data as of . Every figure is the buffer desk's own, on published data.
BAPR vs DOCT
Where each one stands today
DOCT resets first, on Oct 16, 2026, 42 days from now; BAPR runs to Mar 31, 2027, 208 days. BAPR can still gain 6.0% before its cap, DOCT 0.9%. A fall from here reaches BAPR’s buffer after 10.6% and DOCT’s after 14.3%. Both track SPY, so what separates them is where each is in its own period.
Every figure is the buffer desk’s own, from the issuer’s published outcome-period terms. A buffer ETF holds FLEX options on its reference index rather than shares, so there is no holdings overlap between two of them to report.
Performance, window by window
| Window | Total return | Gap to the reference | ||
|---|---|---|---|---|
| BAPR | DOCT | BAPR | DOCT | |
| 3 months | +3.5% | +3.3% | −1.2 pts | −1.4 pts |
| 6 months | +13.2% | +8.5% | −2.0 pts | −6.7 pts |
| 1 year | +17.5% | +12.5% | −2.4 pts | −7.5 pts |
| 3 years | +50.8% | +34.7% | −27.1 pts | −43.3 pts |
| BAPR Innovator U.S. Equity Buffer ETF - Apr | DOCT FT Vest U.S. Equity Deep Buffer ETF - October | |
|---|---|---|
| Issuer | Innovator | First Trust |
| Reference index | SPY | SPY |
| Buffer | ||
| Outcome period | Mar 31, 2026 to Mar 31, 2027 | Oct 20, 2025 to Oct 16, 2026 |
| Days left | 208 | 42 |
| Starting cap | +18.5% | +11.7% |
| Can still gain | 6.0% | 0.9% |
| Fall before buffer | 10.6% | 14.3% |
| Protection left, index points | 9.0% of 9.0% | 25.0% of 25.0% |
| Index return this period | +18.4% | +15.9% |
| Fund return this period | +11.4% | +9.8% |
| State today | Open | At cap |
| Expense ratio | 0.79% | 0.85% |
BAPR in plain words
From its price on Sep 4, 2026, the fund can gain about 6.0% more before it reaches its cap. The fund's price can fall 10.6% from here before the buffer starts absorbing losses, by the issuer's figure. In index terms, SPY can fall 15.6% from today's level to the point where the buffer begins. Protection left, in index points: 9.0% of the 9.0% buffer still sits below today's SPY level. 208 days remained on Sep 4, 2026. On Mar 31, 2027 the period ends and a new cap is set.
DOCT in plain words
SPY had already risen past this fund's cap of +11.7% for the period on Sep 4, 2026, so in index terms there is no more upside to collect. The fund's own price can still drift up to about 0.9% as the period runs out. The fund's price can fall 14.3% from here before the buffer starts absorbing losses, by the issuer's figure. In index terms, SPY can fall 18.0% from today's level to the point where the buffer begins. Protection left, in index points: 25.0% of the 25.0% buffer still sits below today's SPY level. 42 days remained on Sep 4, 2026. On Oct 16, 2026 the period ends and a new cap is set.
Questions people ask
- Which has more room to gain, BAPR or DOCT?
- From their prices on Sep 4, 2026, BAPR can gain about 6.0% before its cap and DOCT about 0.9%, so BAPR has more room left this period.
- Which resets first, BAPR or DOCT?
- BAPR ends its outcome period on Mar 31, 2027 and DOCT on Oct 16, 2026. A new cap is set the day after each.
- Which is cheaper, BAPR or DOCT?
- BAPR charges 0.79% a year and DOCT charges 0.85%, so BAPR is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, BAPR against DOCT, data as of Sep 4, 2026. https://etfiq.com/compare/buffer/BAPR-DOCT.html Free to use with attribution; the underlying files are at Open data.